38 Sidney Street
David Schenkein, MD
Agios Pharmaceuticals, Inc.
Agios (NASDAQ: AGIO) is a publicly traded biopharmaceutical company passionately committed to applying its scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and inborn errors of metabolism, or IEMs, which are a subset of orphan genetic metabolic diseases.
Doug Cole is on the Board of Directors.